Supplement Industry Wants Answers From FDA Transparency Task Force
This article was originally published in The Tan Sheet
Executive Summary
Supplement industry leaders want FDA's Transparency Task Force to shed light on the agency's decision-making process and explain controversial and ambiguous policies as well as improve communication
You may also be interested in...
Information Disclosure Issues Challenge FDA Transparency Task Force
FDA questions whether to disclose information on product applications that a company abandons before approval or in some cases on applications in which review is still pending
Transparency comments through Nov. 6
FDA accepts comments on its transparency initiative through Nov. 6, after which the Transparency Task Force will conduct its second public meeting. The agency's transparency Web site, which features a blog about the initiative, will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Tan Sheet" June 8, 2009)
Drug, Supplement Industries Need Formal But Timely Guidance - Stakeholders
Food and drug industry stakeholders suggest FDA clarify regulatory expectations and justify requirements through written and finalized formal guidance rather than through speeches and other informal communications